LGT Fund Management Co Ltd. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

LGT Fund Management Co Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 560 shares of the biopharmaceutical company’s stock after purchasing an additional 108 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Regeneron Pharmaceuticals were worth $399,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Proficio Capital Partners LLC lifted its holdings in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after acquiring an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $127,489,000. KBC Group NV increased its position in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC increased its position in Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Finally, State Street Corp increased its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $684.87 on Tuesday. The stock has a 50 day moving average price of $697.91 and a 200 day moving average price of $862.68. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $74.87 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $11.86 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.